The UK’s Competition Appeal Tribunal has ruled against a decision by the Competition and Markets Authority that Pfizer and Flynn Pharma breached competition law by charging excessive prices for phenytoin sodium capsules for epilepsy. Disappointed with the judgement, the CMA has warned that active investigations into alleged price gouging may be “severely delayed” as a result.
But Pfizer which appealed against the CMA’s 2016 ruling and record fines, has welcomed the tribunal’s findings. “We are pleased...








